Enovis Corporation

Fundamentals4.0
Price Action6.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • High gross margin
  • Large operating losses
  • Leverage/cash strain

AI
AI Summary

5.0

Enovis has shifted from a balance-sheet speculation to an execution-dependent operational-recovery trade—its 2026 margin guidance and early gross‑margin gains make re-rating plausible, but the case only holds if management sustainably converts modest free cash flow into material debt reduction and avoids new impairments. Monitor sequential quarters for validated margin expansion, rising FCF and measurable leverage decline (or a failed quarter that re-triggers refinancing/impairment risk).

Recovery
Leverage
Execution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • High gross margin
  • Large operating losses
  • Leverage/cash strain

Enovix combines strong product-level gross margins and tangible book support with deep operating losses, high leverage and limited cash versus near-term liabilities, making it a risky turnaround play.

LeverageRisk
ValueMismatch

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Mild short-term weakness
  • Support holding at $25.3–$25.8
  • Downside risk to $21.63

ENOV shows mild weakness over the last month with the price below the last-month average after pulling back from early-March highs, holding resistance-turned-support near $25.3–$25.8 but risking a deeper drop if it breaks $21.63 (key near-term support $22.3).

Rangebound
DownsideRisk
Support Level: $22.3 (secondary $21.63)
Resistance Level: $25.3–$25.8

~18% high-to-low range from $25.79 (2026-03-04) to $21.63 (2026-02-17) indicating elevated volatility

Sentiment & News

6.0

Key News Insights:

  • Beat EPS
  • Growth outlook
  • Institutional buying

Enovis beat Q4 EPS and reported strong 2025 performance despite late-year execution issues, issued a growth- and margin-focused 2026 outlook, and drew institutional buying alongside sizable analyst upside (~76.6% mean target).

Upside
Execution

The upbeat guidance and analyst revisions favor further share appreciation, but execution shortcomings pose a near-term risk to sustained momentum